| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10885862 | Drug Discovery Today | 2015 | 4 Pages |
Abstract
People at ultra-high risk (UHR) of psychosis have â¼30% chance of developing the illness within two years. A range of pharmacological and psychosocial interventions are now available but there is great individual variation in clinical response. Here we examine the evidence for clinically applicable predictors of clinical response in people at UHR of psychosis. We report that currently there are no reliable predictive markers that can be used to optimise treatment. We argue that there is an urgent need for a better understanding of why some people at UHR of psychosis benefit from a certain treatment whereas others do not. This information will help clinicians make more-effective treatment decisions, and improve long-term clinical outcomes in this population.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biotechnology
Authors
Andrea Mechelli, Diana Prata, Charles Kefford, Shitij Kapur,